In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), ...

NCX 470 0.1% demonstrated non-inferiority to latanoprost in lowering IOP, with statistically significant superiority at several timepoints. The Denali trial showed NCX 470 was well tolerated, with ...

An overview of how recent funding reductions are reshaping clinical trial operations, from site sustainability and patient recruitment to trial design and long-term strategy.

In this episode of the Applied Clinical Trials Brief, we spotlight a recent video interview in which Jon Walsh, founder and ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.